Schering-Plough Fungal Treatment Approved in EU
Posted on: Thursday, 9 November 2006, 15:00 CST
The European Commission has granted marketing approval to Schering-Plough for Noxafil in the prevention of invasive fungal infections in high-risk patients.
High-risk patients include those receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes and hematopoietic stem cell transplant recipients. Invasive fungal infections most often occur in people who have compromised immune systems and are a leading cause of death in these high-risk populations.
"In patients with a compromised immune system, invasive fungal infections are very serious and can be difficult to treat once they've become established, so preventing these infections in the first place is critically important for these seriously ill patients," aid Oliver Cornely, University of Cologne, Germany.
The European Commission also approved Noxafil for oropharyngeal candidiasis (OPC), as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor. OPC is a fungal infection of the mouth and throat.
The Commission approval of these indications for Noxafil results in marketing authorization with unified labeling that is valid in the EU as well as in Iceland and Norway. Noxafil was previously approved in the EU and Australia for the treatment of certain invasive fungal infections in patients who are intolerant of certain commonly used antifungal agents.
Source: Datamonitor
Related Articles
- Invasive Fungal Infections in HSCT Recipients: Improving Outcomes Through Prevention and Treatment
- Interim Results From a New Trial of CANCIDAS(R) (Caspofungin Acetate) in Pediatric Patients With Documented Fungal Infections
- The New England Journal Of Medicine Publishes Two Landmark Studies Of NOXAFIL(R) (Posaconazole) in the Prevention of Invasive Fungal Infections
- Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections
- FDA Approves Noxafil(R) (Posaconazole) Oral Suspension For Prevention of Life-Threatening Fungal Infections In High-Risk Patients
- European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk
- FDA Grants Fast Track Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for Prevention of Pulmonary Fungal Infections in At-Risk Patients; First Inhaled Anti-Fungal Therapy Under Development for Immunosuppressed Patients
- Nektar Announces That U.S. FDA Has Granted Orphan Drug Designation to the First Amphotericin B Inhalation Powder to Prevent Pulmonary Fungal Infections in Immunosuppressed Patients
- Nektar Announces Inhaled Amphotericin B Product in Human Clinical Trials for Preventing Fatal Pulmonary Fungal Infections in Immunosuppressed Patients
- European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (Posaconazole) Oral Suspension for Treatment of Invasive Fungal Infections
 |
 |
User Comments (0)
RSS Feeds